江苏荃信生物医药股份有限公司（荃信生物-B，股票代码：02509）于2026年7月9日发布公告，称公司当日通过香港联交所场内回购3,000股H股，占回购前已发行股本的约0.001343%。本次回购价格为每股15.08港元，总耗资约4.52万港元。
公告显示，回购完成后，公司已发行股本总数仍为227,071,600股，其中不含库存股份的已发行股本由223,373,200股下降至223,370,200股，库存股份数量由3,698,400股增至3,701,400股。公司购回授权决议于2026年5月29日获通过，授权可回购股份总数为22,436,340股，截至目前已累计回购993,200股，占购回授权决议获通过当日已发行股本的约0.4427%。本次回购后，公司在新股发行及库存股份出售或转让方面将适用的暂止期截至2026年8月8日。
公司在公告中确认，本次回购已遵守香港联合交易所有限公司证券上市规则及相关法律法规。本公告由董事会秘书和联席公司秘书胡衍保签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.